US GAO says FDA medical products oversight is "high risk"
This article was originally published in Scrip
Executive Summary
The US FDA's oversight of drugs and medical devices is a "high risk area" in need of broad-based transformation to protect the public health, the US Government Accountability Office(GAO), Congress's investigative arm, says in a new report.